Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VERTEX PHARMACEUTICALS

(VRTX)
  Report
Delayed Quote. Delayed Nasdaq - 07/23 04:00:00 pm
200.5 USD   +2.29%
07/23DGAP-NEWS : Il settore delle biotecnologie -2-
DJ
07/23PRESS RELEASE : Solid second quarter for the -2-
DJ
07/21NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vertex Pharmaceuticals Down Over 8%, Worst Performer in The S&P 500 and Nasdaq 100 So Far Today -- Data Talk

06/11/2021 | 10:53am EDT

Vertex Pharmaceuticals Incorporated (VRTX) is currently at $198.12, down $18.65 or 8.6%

-- Would be lowest close since Nov. 7, 2019, when it closed at $195.83

-- On pace for largest percent decrease since Oct. 15, 2020, when it fell 20.7%

-- Snaps a three day winning streak

-- Down 5.04% month-to-date

-- Down 16.17% year-to-date

-- Down 34.63% from its all-time closing high of $303.10 on July 20, 2020

-- Down 26.23% from 52 weeks ago (June 12, 2020), when it closed at $268.56

-- Down 34.63% from its 52-week closing high of $303.10 on July 20, 2020

-- Would be a new 52-week closing low

-- Traded as low as $193.00; lowest intraday level since Oct. 28, 2019, when it hit $192.32

-- Down 10.97% at today's intraday low; largest intraday percent decrease since Oct. 15, 2020, when it fell as much as 21.47%

-- Worst performer in the S&P 500 today

-- Worst performer in the Nasdaq 100 today

-- Third most active stock in the Nasdaq 100 today

All data as of 10:32:45 AM

Source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

06-11-21 1052ET

All news about VERTEX PHARMACEUTICALS
07/23DGAP-NEWS : Il settore delle biotecnologie -2-
DJ
07/23PRESS RELEASE : Solid second quarter for the -2-
DJ
07/21NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
07/20VERTEX PHARMACEUTICALS : SVB Leerink Downgrades Vertex Pharmaceuticals to Underp..
MT
07/19VERTEX PHARMACEUTICALS : Begins Phase 2 Clinical Trial Program for VX-548 to Tre..
MT
07/19VERTEX PHARMACEUTICALS : to Announce Second-Quarter 2021 Financial Results on Ju..
AQ
07/19VERTEX PHARMACEUTICALS : Initiates Phase 2 Clinical Trial Program for VX-548 for..
BU
07/19Vertex Pharmaceuticals Incorporated Initiates Phase 2 Clinical Trial Program ..
CI
07/16VERTEX PHARMACEUTICALS : to Announce Second-Quarter 2021 Financial Results on Ju..
BU
07/08VERTEX PHARMACEUTICALS : RBC Capital Adjusts Vertex Pharmaceuticals PT to $246 F..
MT
More news
Financials (USD)
Sales 2021 6 993 M - -
Net income 2021 1 868 M - -
Net cash 2021 8 140 M - -
P/E ratio 2021 27,9x
Yield 2021 -
Capitalization 51 903 M 51 903 M -
EV / Sales 2021 6,26x
EV / Sales 2022 5,30x
Nbr of Employees 3 400
Free-Float 99,9%
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | MarketScreener
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 200,50 $
Average target price 259,35 $
Spread / Average Target 29,4%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS-15.16%50 308
GILEAD SCIENCES, INC.18.47%85 134
WUXI APPTEC CO., LTD.37.17%71 226
REGENERON PHARMACEUTICALS21.37%57 013
BIONTECH SE245.88%55 555
BEIGENE, LTD.22.66%33 627